TrialThe Lancet. Infectious diseases2015

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.

Anita Kohli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.